Silica nanoparticles are showing serious promise against aggressive prostate cancer. In mouse studies, Cornell-developed "C' dots" triggered tumor cell self-destruction and flipped the immune environment from "cold" to "hot." Combined with immunotherapy, the treatment produced complete remissions in up to half of treated mice — with human trials on the horizon.
Researchers at Weill Cornell Medicine have engineered ultrasmall silica nanoparticles — called Cornell Prime dots (C' dots) — that attack prostate cancer on multiple fronts simultaneously. In preclinical mouse models of aggressive prostate cancer, the particles triggered ferroptosis (a form of oxidative cell self-destruction), reshaped the tumor's immune environment from immune-suppressing to immune-activating, and disrupted cancer cell metabolism — all while leaving healthy tissue unharmed.
The particles were fitted with a targeting molecule that homes in on PSMA, a protein abundant on prostate tumor cells. When combined with immune checkpoint blockade therapy, the treatment produced complete or near-complete remissions in 4 out of 10 mice. Adding a third agent targeting tumor-associated macrophages pushed that number to 5 out of 10.
By the Numbers:
Why it matters: Durable immunotherapy responses in prostate cancer have historically been hard to achieve. This dual-action approach — directly killing tumor cells while simultaneously remodeling the immune microenvironment — could represent a new clinical paradigm. The research team is now working toward human clinical trials.
